Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Raw data of influencing factors. by Jie Huang (104235)

“…Spatially, the CCD demonstrates a characteristic pattern of decreasing from east to west. …”

Data_Sheet_10_Global burden of multiple sclerosis and its attributable risk factors, 1990–2019.PDF by Saeid Safiri (3713035)

“…</p>Conclusion<p>Although the global age-standardized DALY rate of MS decreased between 1990 and 2019, MS continues to account for a considerable number of DALYs and prevalent cases. …”

Data_Sheet_2_Global burden of multiple sclerosis and its attributable risk factors, 1990–2019.PDF by Saeid Safiri (3713035)

“…</p>Conclusion<p>Although the global age-standardized DALY rate of MS decreased between 1990 and 2019, MS continues to account for a considerable number of DALYs and prevalent cases. …”

Evaluation standards of the CCD. by Jie Huang (104235)

“…Spatially, the CCD demonstrates a characteristic pattern of decreasing from east to west. …”

Data_Sheet_14_Global burden of multiple sclerosis and its attributable risk factors, 1990–2019.PDF by Saeid Safiri (3713035)

“…</p>Conclusion<p>Although the global age-standardized DALY rate of MS decreased between 1990 and 2019, MS continues to account for a considerable number of DALYs and prevalent cases. …”

Direct and indirect effects. by Jie Huang (104235)

“…Spatially, the CCD demonstrates a characteristic pattern of decreasing from east to west. …”

Image_1_Global burden of multiple sclerosis and its attributable risk factors, 1990–2019.JPEG by Saeid Safiri (3713035)

“…</p>Conclusion<p>Although the global age-standardized DALY rate of MS decreased between 1990 and 2019, MS continues to account for a considerable number of DALYs and prevalent cases. …”

Raw Data by Kevin Gries (21956942)

“…These findings indicate that a single day of reduced physical activity can elicit modest but significant changes in the metabolic and transcriptomic exercise response. …”

Data_Sheet_12_Global burden of multiple sclerosis and its attributable risk factors, 1990–2019.PDF by Saeid Safiri (3713035)

“…</p>Conclusion<p>Although the global age-standardized DALY rate of MS decreased between 1990 and 2019, MS continues to account for a considerable number of DALYs and prevalent cases. …”

Table_1_Global burden of multiple sclerosis and its attributable risk factors, 1990–2019.DOC by Saeid Safiri (3713035)

“…</p>Conclusion<p>Although the global age-standardized DALY rate of MS decreased between 1990 and 2019, MS continues to account for a considerable number of DALYs and prevalent cases. …”

Combating Chemoresistance in Breast Cancer: Exploring Tumor Microenvironment, Combination Therapies, and Drug Repurposing Strategies by Shazia Sofi (17764488)

“…Chemoresistance in cancer can arise from a variety of molecular mechanisms, including active drug expulsion (drug efflux), decreased drug uptake, enhanced DNA repair mechanisms, the ability of cancer cells to evade programmed cell death (apoptosis), the diversity in the population of cancer cells within a tumor (tumor heterogeneity), and significant alterations in the tumor microenvironment (TME), where interactions between cancer cells, cancer-associated fibroblasts, immune cells, and the extracellular matrix contribute to a supportive environment that allows tumors to survive treatment and escape therapy. …”